TY - JOUR
T1 - Galectin-3 in Heart Failure
T2 - An Update of the Last 3 Years
AU - Gehlken, Carolin
AU - Suthahar, Navin
AU - Meijers, Wouter C.
AU - de Boer, Rudolf A.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/1
Y1 - 2018/1
N2 - Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3–centered diseases.
AB - Galectin-3 plays a role in tissue inflammation, repair, and fibrosis. This article specifically focuses on heart failure (HF), in which galectin-3 has been shown to be a useful biomarker in prognosis and risk stratification, especially in HF with preserved ejection fraction. Experimental research has shown that galectin-3 directly induces pathologic remodeling of the heart, and is therefore considered a culprit protein in the development of cardiac fibrosis in HF, with potentially relevant clinical implications. In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3–centered diseases.
UR - http://www.scopus.com/inward/record.url?scp=85034211410&partnerID=8YFLogxK
U2 - 10.1016/j.hfc.2017.08.009
DO - 10.1016/j.hfc.2017.08.009
M3 - Review article
C2 - 29153203
AN - SCOPUS:85034211410
SN - 1551-7136
VL - 14
SP - 75
EP - 92
JO - Heart Failure Clinics
JF - Heart Failure Clinics
IS - 1
ER -